Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Doil Liniment is a topical analgesic formulation developed by Anthus Pharmaceuticals for the management of musculoskeletal pain, including conditions like osteoarthritis and rheumatoid arthritis. It is a multi-ingredient small molecule product containing diclofenac, capsaicin, menthol, and camphor in a dimethyl sulfoxide (DMSO) base. Diclofenac serves as a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce pain and inflammation. Capsaicin acts as a counter-irritant and desensitizes nociceptors by depleting substance P. Menthol and camphor provide cooling and warming sensations, respectively, which help distract from pain through sensory stimulation. The DMSO base enhances the skin penetration of the active ingredients, allowing for effective localized treatment of muscle and joint pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Doil Liniment.